454 related articles for article (PubMed ID: 27347680)
1. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
3. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
5. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
[TBL] [Abstract][Full Text] [Related]
6. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.
Ambade A; Lowe P; Kodys K; Catalano D; Gyongyosi B; Cho Y; Iracheta-Vellve A; Adejumo A; Saha B; Calenda C; Mehta J; Lefebvre E; Vig P; Szabo G
Hepatology; 2019 Mar; 69(3):1105-1121. PubMed ID: 30179264
[TBL] [Abstract][Full Text] [Related]
9. Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury.
Puengel T; Krenkel O; Kohlhepp M; Lefebvre E; Luedde T; Trautwein C; Tacke F
PLoS One; 2017; 12(9):e0184694. PubMed ID: 28910354
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy.
Kwiatkowski K; Pawlik K; Ciapała K; Piotrowska A; Makuch W; Mika J
Front Immunol; 2020; 11():615327. PubMed ID: 33408720
[TBL] [Abstract][Full Text] [Related]
12. Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations.
Lowe PP; Morel C; Ambade A; Iracheta-Vellve A; Kwiatkowski E; Satishchandran A; Furi I; Cho Y; Gyongyosi B; Catalano D; Lefebvre E; Fischer L; Seyedkazemi S; Schafer DP; Szabo G
J Neuroinflammation; 2020 Oct; 17(1):296. PubMed ID: 33036616
[TBL] [Abstract][Full Text] [Related]
13. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.
Bowler S; Siriwardhana C; Mitchell BI; D'Antoni ML; Ogata-Arakaki D; Souza S; Yee R; Gangcuangco LMA; Chow DC; Ndhlovu LC; Shikuma C
HIV Res Clin Pract; 2019; 20(4-5):123-129. PubMed ID: 32013805
[No Abstract] [Full Text] [Related]
14. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
15. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
[TBL] [Abstract][Full Text] [Related]
16. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Files DC; Tacke F; O'Sullivan A; Dorr P; Ferguson WG; Powderly WG
PLoS Pathog; 2022 Jun; 18(6):e1010547. PubMed ID: 35749425
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.
Kwiatkowski K; Ciapała K; Rojewska E; Makuch W; Mika J
Int Immunopharmacol; 2020 Jul; 84():106540. PubMed ID: 32402949
[TBL] [Abstract][Full Text] [Related]
18. Role of cenicriviroc in the management of nonalcoholic fatty liver disease.
Neokosmidis G; Tziomalos K
World J Gastroenterol; 2018 Dec; 24(48):5415-5417. PubMed ID: 30622370
[TBL] [Abstract][Full Text] [Related]
19. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Lefere S; Devisscher L; Tacke F
Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
[No Abstract] [Full Text] [Related]
20. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data.
Diaz Soto MP; Lim JK
Hepat Med; 2020; 12():115-123. PubMed ID: 32884369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
